Skip to content
    IDXX
    Earnings call· Sep 2025(Q3 FY25)

    IDEXX LABORATORIES INC /DE IDXX

    Nov 3, 2025 Source

    Executive summary

    IDEXX Q3 FY25 — Strong CAG Diagnostics Growth & InVue Dx Momentum

    IDEXX delivered strong Q3 FY25 results, driven by robust commercial execution and innovation in its Companion Animal Group, particularly with InVue Dx and Catalyst Cortisol. Despite ongoing macro pressures impacting U.S. clinical visits, the company achieved significant organic revenue growth and margin expansion, leading to an increased full-year outlook. Strategic investments in commercial capabilities and R&D are expected to sustain long-term growth, especially in international markets and through expanding its diagnostic portfolio.

    Highlights

    5

    • CAG Diagnostics recurring revenues grew over 10% organically, with 8% in the U.S. and double-digit internationally.

    • IDEXX InVue Dx analyzer placements reached 1,750 in Q3, contributing to 71% organic growth in CAG instrument revenues.

    • Comparable operating margin expanded by 120 basis points, driven by gross margin expansion.

    • Comparable EPS grew 15% to $3.40 in the quarter.

    • Full-year revenue outlook increased by $43 million at midpoint, and EPS outlook raised by $0.33 per share at midpoint.

    Concerns

    3

    • U.S. same-store clinical visits declined 1.2% in Q3, driven by macro and sector pressures.

    • Wellness visits declined 2.5% in Q3.

    • Global rapid assay revenues declined 5% organically, impacted by customers shifting pancreatic lipase testing to Catalyst instrument platform, representing a 6% headwind.

    Guidance & targets

    19
    CategoryTargetConfidence
    Full-year revenue outlook
    $4.270 billion to $4.300 billion
    high materiality
    High
    Full-year overall reported revenue growth
    9.6% to 10.3%
    high materiality
    High
    Full-year overall organic revenue growth
    8.8% to 9.5%
    high materiality
    High
    Full-year organic CAG Diagnostics recurring revenue growth
    7.5% to 8.2%
    high materiality
    High
    Full-year EPS outlook
    $12.81 to $13.01 per share
    high materiality
    High
    Full-year comparable EPS growth
    12% to 14%
    high materiality
    High
    Full-year free cash flow conversion
    95% to 100% of net income
    medium materiality
    High
    Full-year capital spending
    approximately $140 million
    medium materiality
    High
    Full-year InVue Dx placements
    approximately 6,000
    high materiality
    High
    Full-year InVue Dx instrument revenues
    over $65 million
    high materiality
    High
    Full-year reported operating margin outlook
    31.6% to 31.8%
    high materiality
    High
    Full-year comparable operating margin improvement
    80 to 100 basis points
    high materiality
    High
    Q4 U.S. clinical visits trend
    decline at levels moderately better than the year-to-date average
    medium materiality
    Medium
    International sales force expansion
    3 international countries
    low materiality
    High
    U.S. commercial footprint enhancement
    modest increment
    low materiality
    High
    Cancer Dx panel expansion
    mast cell tumor and another high-impact cancer biomarker
    medium materiality
    High
    Cancer Dx international launch
    international markets
    medium materiality
    High
    InVue Dx FNA rollout
    fine needle aspirate
    medium materiality
    High
    InVue Dx long-term placements
    20,000 over 5 years
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Companion Animal Group (CAG)
    Strong results driven by recurring revenue growth and significant instrument placements.
    CAG Diagnostics recurring revenue growth: 10% organicU.S. CAG Diagnostics recurring revenue growth: 8%International CAG Diagnostics recurring revenue growth: 14% organicCAG Diagnostic instrument revenues growth: 71% organic
    		—12% organic——
    Water
    Strong growth in international regions and solid mid-single-digit growth in the U.S.
    		—7% organic——
    Livestock, Poultry and Dairy (LPD)
    Double-digit gains across most regions.
    		—14% organic——

    Operational metrics

    44
    Comparable EPS
    $3.4015% growth
    Q3 FY25

    Enabled by high operating profit gains.

    Comparable Gross Margin
    61.8%Up 80 bps
    Q3 FY25

    Reflects benefits from strong recurring revenue growth and operational productivity, offsetting inflationary costs.

    Foreign Exchange Impact on Operating Profit
    $1.9 million
    Q3 FY25

    Net of hedge effects.

    Foreign Exchange Impact on EPS
    $0.02
    Q3 FY25

    Net of hedge effects.

    EPS Operational Improvement
    $0.22at midpoint compared to prior guide
    FY25

    Incorporated into the updated full-year EPS outlook.

    U.S. Same-Store Clinical Visits
    -1.2%Decline
    Q3 FY25

    Driven by ongoing macro and sector pressures.

    Wellness Visits
    -2.5%Declined
    Q3 FY25

    Reflecting continued pressure on elective and wellness characteristics.

    Non-Wellness Visits
    -0.3%Declined
    Q3 FY25

    Closer to flat year-over-year, benefiting from aging pet population.

    CAG Diagnostics Recurring Revenue Growth Premium to U.S. Clinical Visits
    950
    Q3 FY25

    Highlights outstanding performance by IDEXX teams despite visit declines.

    Global Net Price Realization
    4% to 4.5%
    Q3 FY25

    Benefit to CAG Diagnostics recurring revenue growth.

    International CAG Diagnostics Recurring Revenue Days Benefit
    1%
    Q3 FY25

    Benefit related to equivalent days.

    IDEXX VetLab Consumable Revenues Growth
    16%Organic
    Q3 FY25

    Reflecting double-digit growth in both U.S. and international regions.

    InVue Dx Recurring Revenue Estimate
    $3,500 to $5,500
    Annual

    Per analyzer, tracking well to expectations.

    Total Premium Placements
    5,66537% increase YoY
    Q3 FY25

    Significant increase compared to prior year levels.

    Global New and Competitive Catalyst Placements
    1,203
    Q3 FY25

    Reflects high quality of placements.

    North America Catalyst Placements
    347
    Q3 FY25

    Part of global new and competitive placements.

    IDEXX InVue Dx Instruments Placed
    1,753
    Q3 FY25

    Continuing to meet customer demand for this innovative analyzer.

    Premium Instrument Installed Base Growth
    10%YoY
    Q3 FY25

    Supported by ongoing placements and high customer retention.

    Global Reference Lab Revenues Growth
    9%Organic
    Q3 FY25

    Up approximately 4% growth from Q2, driven by solid volume growth.

    IDEXX Cancer Dx Customers
    5,000
    Through October

    Gaining further traction.

    Global Rapid Assay Revenues Growth
    -5%Organic
    Q3 FY25

    Impacted by customers shifting pancreatic lipase testing to Catalyst platform.

    Rapid Assay Headwind from Catalyst Shift
    6%
    Q3 FY25

    Estimated impact on Q3 revenue growth.

    Veterinary Software and Diagnostic Imaging Organic Revenues Growth
    11%
    Q3 FY25

    Driven by recurring revenues.

    Recurring Software Revenues Growth
    10%
    Q3 FY25

    Solid growth in veterinary software.

    Operating Expenses Growth
    12%YoY
    Q3 FY25

    As the company advances investments in global commercial and innovation capabilities.

    Share-Based Compensation Benefit
    $14 million
    Q3 FY25

    Benefit included in Q3 EPS.

    Income Tax Negative Impact (Research Deductions)
    $0.09
    Q3 FY25

    Related to accelerating tax deductions for previously incurred research expenses allowed under new U.S. tax legislation.

    Leverage Ratio (Gross)
    0.7x
    Q3 FY25

    Balance sheet remains strong.

    Leverage Ratio (Net of Cash)
    0.5x
    Q3 FY25

    Balance sheet remains strong.

    Share Repurchases
    $242 million
    Q3 FY25

    Allocated during the third quarter.

    Year-to-Date Share Repurchases
    $985 million
    YTD Q3 FY25

    Supporting reduction in diluted shares outstanding.

    Diluted Shares Outstanding Reduction
    2.7%YoY
    Through Q3 FY25

    Supported by share repurchases.

    Full Year FX Revenue Benefit
    0.8%
    FY25

    At the rates outlined in the press release.

    FX Sensitivity (1% USD strengthening)
    $4 million
    Remainder of FY25

    Reduction in revenue and EPS for the remainder of the year.

    Cash Tax Benefit (Research Deductions)
    10%
    FY25

    Primarily related to acceleration of tax deductions for previously incurred research expenses.

    InVue Dx Placements
    4,400
    YTD Q3 FY25

    Exceeding expectations and reinforcing momentum.

    Catalyst Cortisol Adoption
    25%
    First 3 months of launch

    Among the fastest adoptions for Catalyst menu expansion.

    Catalyst Installed Base
    77,000
    Q3 FY25

    Each new menu expansion represents a lever for increased utilization.

    Catalyst Pancreatic Lipase Adoption
    50%
    Q3 FY25

    Achieved adoption across over half of the available installed base.

    Cancer Dx Competitive Customer Adoption
    17%
    Q3 FY25

    Reflects growing awareness and importance of Cancer Dx.

    Cloud-Native PIMS Platforms Installed Base
    10,000
    Q3 FY25

    Surpassing a milestone with strong adoption.

    Vello Active Clinics Growth
    20%Sequentially
    Q3 FY25

    Client engagement platform continued to expand.

    PIMS Bookings with Vello Subscription
    50%
    Q3 FY25

    Over half of PIMS bookings included a Vello subscription.

    International CAG Diagnostics Recurring Growth Potential
    13% to 16%
    Long-term

    Guided at Investor Day as faster than U.S. opportunity.

    Industry KPIs

    10
    MetricValueDetails
    System utilization$3,500 to $5,500USD
    Pricing realized price4% to 4.5%%
    New product launch rampCatalyst Cortisol: >25% adoption; InVue Dx: >4,400 YTD placements%
    Procedure volume growthU.S. same-store clinical visits: -1.2%; Wellness visits: -2.5%; Non-wellness visits: -0.3%%
    FCF conversion leverage guidanceFCF conversion: 94% (Q3 FY25); 95%-100% (FY25 outlook)%
    Installed base system placements5,665 units (Total premium placements); 1,753 instruments (IDEXX InVue Dx placed)units
    Segment franchise organic growthCAG Diagnostics recurring: 10% organic; IDEXX VetLab consumable: 16% organic; Global Reference Lab: 9% organic; Veterinary software and diagnostic imaging: 11% organic%
    Consumables recurring revenue mix16%%
    Sales force commercial capacity build—
    Indicated addressable patient population—

    Product announcements

    2
    ProductTypeDetails
    Catalyst Cortisollaunch
    InVue Dx Fine Needle Aspirate (FNA)launch

    Risks & headwinds

    5
    U.S. same-store clinical visits declineQ3 FY25

    1.2% decline in Q3

    Mitigation: Strong commercial execution and innovation (e.g., InVue Dx, Catalyst menu expansion) leading to a 950 bps premium over visit trends; benefits from aging pet population expected long-term.

    Wellness visits declineQ3 FY25

    2.5% decline in Q3

    Mitigation: Focus on expanding Cancer Dx panel for screening, which will become more compelling as the menu expands; long-term tailwind from aging pets shifting to sick care.

    Rapid assay revenue decline due to shift to CatalystQ3 FY25

    5% organic decline in Q3, 6% headwind from Catalyst shift

    Mitigation: Customers shifting to Catalyst instrument platform for pancreatic lipase testing, which is a strategic shift to a higher-value platform for IDEXX.

    Inflationary cost pressuresOngoing

    Discussed, not quantified

    Mitigation: Offset by gross margin expansion, strong recurring revenue growth, operational productivity, and pricing benefits.

    Ongoing changes in the trade landscapeInto 2026

    Discussed, not quantified

    Mitigation: Largely U.S.-based manufacturing footprint; actively managing cost impacts and ensuring continuous supply to customers.

    What to watch in Q4 FY25

    5

    InVue Dx Placements and Revenue Ramp

    Next quarter (Q4 FY25)
    Current>4,400 YTD placements, >$65M FY25 instrument revenue target
    TargetContinued strong placements towards ~6,000 FY25 target and revenue contribution

    Why it matters

    InVue Dx is a key innovation driving instrument revenue and future recurring consumables, critical for overall growth.

    We are again increasing our expectations for our InVue Dx placements, which we now expect to be approximately 6,000 during 2025, with instrument revenues of over $65 million as we continue to see strong demand from this exciting new platform.

    Q&A highlights

    7

    How much of the consumables growth is attributable to InVue Dx, new contracting terms, or other factors, and is there a metric for consumables uplift per InVue Dx placement similar to past Catalyst Dx launches?

    The growth in VetLab consumables is broad-based, driven by the large installed base growth, high-quality placements, and new specialty tests like Catalyst Cortisol. InVue Dx consumables are an early-stage add-on, tracking well to recurring revenue estimates, and are expected to contribute more as the installed base grows. The company noted that this is not a substitution from reference labs to point of care.

    “the growth in the VetLab consumables piece is very broad-based. So there's obviously the large installed base growth of 10%, and you can go back many quarters, and we continue to grow that very aggressively.”

    asked by Erin Wilson Wright · answered by Jay Mazelsky

    2 min read6 chapters

    Detailed Narrative

    01

    Innovation & Product Momentum

    IDEXX highlighted strong momentum across its innovation portfolio. The InVue Dx analyzer saw over 1,750 placements in Q3, with year-to-date placements exceeding 4,400, reinforcing its position as a successful product rollout. Catalyst Cortisol, launched in Q3, achieved rapid adoption with over 25% of Catalyst customers in North America using it within three months. Cancer Dx continues to gain traction with nearly 5,000 customers, and plans are in place to expand its panel with mast cell tumor detection and another biomarker in 2026, alongside international expansion starting Q1 2026.

    02

    Commercial Execution & Customer Engagement

    The company's high-touch commercial model and differentiated solutions drove strong financial performance. This included double-digit growth in the premium instrument installed base, sustained new customer gains, and solid net price realization. Retention of CAG Diagnostics recurring revenue remained in the high 90s, reflecting strong customer loyalty. IDEXX representatives serve as partners, helping practices improve medical outcomes and business performance, leading to increased diagnostic frequency and utilization.

    03

    International Growth Opportunity

    International CAG Diagnostics recurring revenue grew 14% organically in Q3, marking 11 consecutive quarters of double-digit installed base growth. Management sees significant long-term opportunity in international markets, which are considered more embryonic in diagnostic use. Investments in sales force expansion (3 new international countries by early 2026), Reference Lab networks, and localized software solutions are key to developing these markets and achieving a projected 13-16% growth rate.

    04

    Aging Pet Demographics & Clinical Visits

    U.S. same-store clinical visits declined 1.2% in Q3, with wellness visits down 2.5% and non-wellness visits down 0.3%. However, the aging pet population, particularly pandemic-era dogs, is expected to drive increased sick care visits in the future, providing a positive long-term tailwind for clinical visit trends. IDEXX's performance premium to U.S. clinical visits was approximately 950 basis points, demonstrating strong execution despite market headwinds🌐.

    05

    Software & Digital Solutions

    IDEXX's cloud-based software platforms are experiencing broad adoption. Cloud-native PIMS platforms surpassed 10,000 locations, showing strong growth among independent and enterprise customers. Vello, the client engagement platform, saw active clinics grow over 20% sequentially, with over half of PIMS bookings including a Vello subscription. These integrated solutions enhance workflow efficiency, client satisfaction, and drive higher visit volumes and revenue growth for clinics.

    06

    Investment Strategy

    IDEXX continues to make disciplined investments in its business. This includes expanding its commercial footprint in three international countries and modestly in the U.S. by early 2026, which are viewed as high-return, short-term investments. Ongoing R&D investments focus on multi-year horizons for biomarker development, new instruments like Multi-Q Dx, and significant investment in cloud-based PIMS and Vello software applications. These investments are balanced with delivering solid operating margin gains.

    AI-generated summary of the company’s earnings call. Not investment advice.